The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Sign in to access this content
Sign InMindBio Therapeutics has officially completed the development and deployment of its proprietary Intox Collect™ technology. This innovative system utilizes advanced AI-driven voice and facial recognition to identify intoxication from alcohol and various central nervous system (CNS) substances. The deployment marks a significant milestone in the company’s efforts to scale its data collection and analysis infrastructure rapidly. By leveraging AI, MindBio can now process data samples from a broad spectrum of consumed substances for biotechnology and diagnostic purposes. This technology is expected to enhance the company's diagnostic capabilities and market competitiveness in the AI-driven healthcare sector. Investors view this move as a positive step toward increasing the company's valuation through proprietary technological innovation.